Avantax Advisory Services Inc. lessened its position in shares of CVS Health Co. (NYSE:CVS – Free Report) by 20.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 127,891 shares of the pharmacy operator’s stock after selling 33,057 shares during the quarter. Avantax Advisory Services Inc.’s holdings in CVS Health were worth $5,741,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of CVS. MidAtlantic Capital Management Inc. bought a new position in shares of CVS Health during the 3rd quarter worth approximately $25,000. Ridgewood Investments LLC increased its stake in CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 450 shares in the last quarter. Stonebridge Financial Group LLC acquired a new position in CVS Health during the 4th quarter valued at approximately $28,000. Hopwood Financial Services Inc. acquired a new position in CVS Health during the 4th quarter valued at approximately $29,000. Finally, Legacy Investment Solutions LLC acquired a new position in CVS Health during the 3rd quarter valued at approximately $31,000. Institutional investors own 80.66% of the company’s stock.
CVS Health Stock Performance
Shares of NYSE CVS opened at $65.63 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company has a market capitalization of $82.75 billion, a PE ratio of 17.93, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53. CVS Health Co. has a 1 year low of $43.56 and a 1 year high of $80.75. The company’s fifty day moving average price is $58.47 and its 200 day moving average price is $57.00.
CVS Health Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.05%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s payout ratio is 72.68%.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on CVS shares. StockNews.com upgraded shares of CVS Health from a “sell” rating to a “hold” rating in a research note on Thursday, February 13th. Leerink Partnrs upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research note on Tuesday, December 3rd. Edward Jones upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. Finally, TD Cowen increased their price objective on shares of CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $69.83.
Read Our Latest Stock Analysis on CVS Health
Insider Buying and Selling at CVS Health
In other news, SVP James David Clark sold 7,513 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.24% of the company’s stock.
CVS Health Profile
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Recommended Stories
- Five stocks we like better than CVS Health
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- 3 Dividend Kings To Consider
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Which Wall Street Analysts are the Most Accurate?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.